"I had Made the Decision, and No One was Going to Stop Me" -Facilitators of PrEP Adherence During Pregnancy and Postpartum in Cape Town, South Africa

Dvora L Joseph Davey, Lucia Knight, Jackie Markt-Maloney, Nokwazi Tsawe, Yolanda Gomba, Nyiko Mashele, Kathryn Dovel, Pamina Gorbach, Linda-Gail Bekker, Thomas J Coates, Landon Myer, Dvora L Joseph Davey, Lucia Knight, Jackie Markt-Maloney, Nokwazi Tsawe, Yolanda Gomba, Nyiko Mashele, Kathryn Dovel, Pamina Gorbach, Linda-Gail Bekker, Thomas J Coates, Landon Myer

Abstract

PrEP is safe and effective but requires adherence during potential HIV exposure, yet the facilitators of long-term maternal adherence are not well understood. We conducted semi-structured interviews with 25 postpartum women who reported high adherence (PrEP use ≥ 25 days in last 30-days and never missed a PrEP prescription in pregnancy/postpartum period) within a PrEP service for pregnant and postpartum women. A thematic approach guided an iterative process of coding and analysis. Themes identified as drivers of optimal PrEP use were HIV risk perception, mainly because of partner's behaviors and unknown serostatus, and a strong desire to have a baby free of HIV. Reported disclosure of PrEP use facilitated PrEP adherence. Women discussed having partner and family support, which included reminders to take PrEP daily. Primary barriers were anticipated or experienced stigma, overcome through education of partners and family about PrEP. Pregnant women experienced transient side-effects, but found ways to continue, including taking PrEP at night. PrEP programs for pregnant and postpartum women should integrate strategies to assist women with realistic appraisals of risk and teach skills for disclosure and securing support from significant others.

Keywords: HIV prevention; Postpartum; PrEP; Pre-exposure prophylaxis; Pregnancy; South Africa.

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Figures

Fig. 1
Fig. 1
PrEP-PP conceptual model of individual, disease, facility level and pill factors associated with PrEP adherence adapted from Ickovics & Meisler [21]

References

    1. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med. 2014;11(2):e1001608. doi: 10.1371/journal.pmed.1001608.
    1. Mofenson LM. Risk of HIV acquisition during pregnancy and postpartum: a call for action. J Infect Dis. 2018;218(1):1–4. doi: 10.1093/infdis/jiy118.
    1. Mofenson LM. Tenofovir pre-exposure prophylaxis for pregnant and breastfeeding women at risk of hiv infection: the time is now. PLoS Med. 2016;13(9):e1002133. doi: 10.1371/journal.pmed.1002133.
    1. Johnson LF, Stinson K, Newell ML, Bland RM, Moultrie H, Davies MA, et al. 2012 The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV. J Acquir Immune Defic Syndr. 1999;59(4):417–425. doi: 10.1097/QAI.0b013e3182432f27.
    1. Dinh TH, Delaney KP, Goga A, Jackson D, Lombard C, Woldesenbet S, et al. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4–8 weeks postpartum in South Africa 2011–2012: a national population-based evaluation. PLoS ONE. 2015;10(5):e0125525. doi: 10.1371/journal.pone.0125525.
    1. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57(12):1773–1781. doi: 10.1093/cid/cit601.
    1. Ministry of Health NASCP . Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya. Nairobi: Ministry of Health NASCP; 2016.
    1. World Health Organization . WHO technical brief: preventing HIV during pregnancy and breastfeeding in the context of pre-exposure prophylaxis (PrEP) Geneva: World Health Organization; 2017.
    1. Joseph Davey DL, Bekker LG, Gomba Y, Coates T, Myer L, Johnson LF. Modelling the potential impact of providing preexposure prophylaxis in pregnant and breastfeeding women in South Africa. AIDS. 2019;33(8):1391–1395. doi: 10.1097/QAD.0000000000002221.
    1. Joseph Davey DL, Pintye J, Baeten JM, Aldrovandi G, Baggaley R, Bekker LG, et al. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? J Int AIDS Soc. 2020;23(1):e25426. doi: 10.1002/jia2.25426.
    1. Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, et al. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. AIDS. 2018;32(13):1891–1898. doi: 10.1097/QAD.0000000000001922.
    1. Stranix-Chibanda L, Anderson PL, Kacanek D, Hosek S, Huang S, Nematadzira TG, Taulo F, Korutaro V, Nakabiito C, Masenya M, Lypen K, Brown E, Ibrahim ME, Yager J, Wiesner L, Johnston B, Amico KR, Rooney JF, Chakhtoura N, Spiegel HML, Chi BH; IMPAACT 2009 team. Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa. Clin Infect Dis. 2020:ciaa1872. 10.1093/cid/ciaa1872.
    1. Joseph Davey DL, Daniels J, Beard C, Mashele N, Bekker LG, Dovel K, et al. Healthcare provider knowledge and attitudes about pre-exposure prophylaxis (PrEP) in pregnancy in Cape Town South Africa. AIDS Care. 2020;32(10):1290–1294. doi: 10.1080/09540121.2020.1782328.
    1. Joseph Davey D, Bekker LG, Coates TJ, Myer L. Contracting HIV or contracting SAR-CoV-2 (COVID- 19) in pregnancy? balancing the risks and benefits. AIDS Behav. 2020;24(8):2229–2231. doi: 10.1007/s10461-020-02861-x.
    1. Pintye J, Davey DLJ, Wagner AD, John-Stewart G, Baggaley R, Bekker LG, et al. Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. Lancet HIV. 2020;7(8):e582–e592. doi: 10.1016/S2352-3018(20)30102-8.
    1. Philbin MM, Parish C, Kinnard EN, Reed SE, Kerrigan D, Alcaide ML, et al. Interest in long-acting injectable pre-exposure prophylaxis (LAI PrEP) among women in the women's interagency HIV study (WIHS): a qualitative study across six cities in the United States. AIDS Behav. 2021;25(3):667–678. doi: 10.1007/s10461-020-03023-9.
    1. Kuehn BM. Long-acting PrEP shows promise. JAMA. 2020;324(7):621.
    1. Joseph Davey DL, Mvududu R, Mashele N, Lesosky M, Bekker LG, Khadka N, et al. Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: implications for maternal PrEP roll out in South Africa. medRxiv. 2021;7(8):e582.
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi: 10.1191/1478088706qp063oa.
    1. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi: 10.1093/intqhc/mzm042.
    1. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50(4):385–391. doi: 10.1016/S0895-4356(97)00041-3.
    1. Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS ONE. 2015;10(4):e0125458. doi: 10.1371/journal.pone.0125458.
    1. Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. 2016 participants' explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 1999;71(4):452–461. doi: 10.1097/QAI.0000000000000880.
    1. Thirumurthy H, Masters SH, Mavedzenge SN, Maman S, Omanga E, Agot K. Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study. Lancet HIV. 2016;3(6):e266–e274. doi: 10.1016/S2352-3018(16)00041-2.
    1. Masters SH, Agot K, Obonyo B, Mavedzenge SN, Maman S, Thirumurthy H. Promoting partner testing and couples testing through secondary distribution of HIV self-tests: a randomized clinical trial. PLoS Med. 2016;13(11):e1002166. doi: 10.1371/journal.pmed.1002166.
    1. Choko AT, Corbett EL, Stallard N, Maheswaran H, Lepine A, Johnson CC, et al. HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: an adaptive multi-arm, multi-stage cluster randomised trial. PLoS Med. 2019;16(1):e1002719. doi: 10.1371/journal.pmed.1002719.
    1. Gichangi A, Wambua J, Mutwiwa S, Njogu R, Bazant E, Wamicwe J, et al. Impact of HIV self-test distribution to male partners of ANC clients: results of a randomized controlled trial in Kenya. J Acquir Immune Defic Syndr. 2018;79(4):467–473. doi: 10.1097/QAI.0000000000001838.
    1. Ngure K, Trinidad SB, Beima-Sofie K, Baeten JM, Mugo NR, Bukusi EA, et al. The role of male partners in women's participation in research during pregnancy: a case study from the partners demonstration project. Reprod Health. 2017;14(Suppl 3):160. doi: 10.1186/s12978-017-0424-0.
    1. McGrath CJ, Singa B, Langat A, Kinuthia J, Ronen K, Omolo D, et al. Non-disclosure to male partners and incomplete PMTCT regimens associated with higher risk of mother-to-child HIV transmission: a national survey in Kenya. AIDS Care. 2018;30(6):765–773. doi: 10.1080/09540121.2017.1400642.
    1. Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3):e25463. doi: 10.1002/jia2.25463.
    1. Moran A, Mashele N, Mvududu R, Bekker LG, Gorbach P, Coates T, Myer L, Joseph Davey D. Maternal PrEP use in HIV-uninfected pregnant women in South Africa: Role of Stigma in PrEP initiation, retention and adherence. medRxiv 2020. 10.1101/2020.11.24.20237867.
    1. Akinde Y, Groves AK, Nkwihoreze H, Aaron E, Alleyne G, Wright C, et al. Assessing the acceptability of a peer mentor mother intervention to improve retention in care of postpartum women living with HIV. Health Equity. 2019;3(1):336–342. doi: 10.1089/heq.2019.0027.
    1. Kinuthia J, Pintye J, Abuna F, Mugwanya KK, Lagat H, Onyango D, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2020;7(1):e38–48. doi: 10.1016/S2352-3018(19)30335-2.
    1. Pintye J, Beima-Sofie KM, Kimemia G, Ngure K, Trinidad SB, Heffron RA, et al. 2017 "I did not want to give birth to a child who has HIV": experiences using prep during pregnancy among HIV-uninfected Kenyan women in HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 1999;76(3):259–265. doi: 10.1097/QAI.0000000000001516.
    1. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron RA, et al. A risk assessment tool for identifying pregnant and postpartum women who may benefit from preexposure prophylaxis. Clin Infect Dis. 2017;64(6):751–758.
    1. Pintye J, Kinuthia J, Roberts DA, Wagner AD, Mugwanya K, Abuna F, et al. 2018 brief report: integration of PrEP services into routine antenatal and postnatal care: experiences from an implementation program in Western Kenya. J Acquir Immune Defic Syndr. 1999;79(5):590–595. doi: 10.1097/QAI.0000000000001850.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren